Open AccessUsing Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use
Author(s) -
Anna Kemp,
Nicole Pratt,
Emmae Ramsay,
Elizabeth E. Roughead
Publication year - 2018
Publication title -
applied health economics and health policy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.099
H-Index - 40
eISSN - 1179-1896
pISSN - 1175-5652
DOI - 10.1007/s40258-018-0440-4
Subject(s) - aflibercept , ranibizumab , medicine , macular degeneration , listing (finance) , bevacizumab , ophthalmology , business , finance , chemotherapy
To describe how post-market utilisation analysis in Australia informs cost-effectiveness assessment and pricing decisions, using aflibercept and ranibizumab as case studies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom